<DOC>
	<DOCNO>NCT00781573</DOCNO>
	<brief_summary>Although optimal duration clopidogrel ( anti-platelet agent ) therapy establish bare metal stent implantation blood vessel heart , lack consensus regard optimal duration therapy implantation drug elute stent ( DES ) . Current American College Cardiology guideline recommend clopidogrel use least one year absence contraindication DES implantation , recognize optimal duration remain unknown . While extend clopidogrel therapy ( beyond current 1 year recommendation ) may increase bleed complication , may reduce rate adverse cardiovascular event like heart attack repeat revascularization procedure . A clinical trial randomize patient uneventful one year course DES implantation , additional year clopidogrel aspirin therapy versus aspirin alone , able answer important question role extend ( 2y ) dual anti-platelet therapy clopidogrel aspirin DES implant . The investigator hypothesize clopidogrel discontinuation 1 year post-DES implantation associate increase cardiovascular event one year follow-up period .</brief_summary>
	<brief_title>Study Optimal Clopidogrel Duration Patients Receiving Drug Eluting Stents ( SCORE Trial )</brief_title>
	<detailed_description>SCORE multicenter , prospective randomize study post-percutaneous coronary intervention ( PCI ) patient uneventful 1 year post-PCI course dual anti-platelet therapy ( DAPT ) clopidogrel aspirin . Patient randomize additional 1 year DAPT ( treatment arm ) vs. aspirin alone ( control arm ) ass follow endpoint 1 year follow-up period : 1 . Death / Myocardial infarction ( MI ) ( Primary end-point ) 2 . Combined endpoint death , myocardial infarction , repeat revascularization , stroke , major/minor bleeding ( Secondary end-point ) During year follow , subject contact every three month . This enable u track study endpoint study population . In addition patient ' medical record screen investigate aforementioned endpoint reach .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>PostPCI patient receive least 1 DES Completed 915 month followup free MI , repeat revascularization Able provide inform consent Have continue dual antiplatelet therapy aspirin clopidogrel 1 year postPCI Patients allergic aspirin Patients aspirin resistance Patients allergy clopidogrel Patients concomitant warfarin therapy History bleeding diathesis , coagulopathy , and/or platelet count &lt; 100,000 cubic mm Patients life expectancy le 1 year due active cancer ( except basal cell carcinoma ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Drug Eluting Stent</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Optimal duration clopidogrel post DES stent implantation</keyword>
</DOC>